Valuation: Precision Therapeutics Inc

Market Cap 96.21M 85.73M 79.37M 71.83M 135M 9.08B 137M 952M 373M 4.77B 361M 353M 15.21B P/E 2026 *
-4.77x
P/E 2027 * -75.5x
Enterprise Value 96.21M 85.73M 79.37M 71.83M 135M 9.08B 137M 952M 373M 4.77B 361M 353M 15.21B EV / Sales 2026 *
1.59x
EV / Sales 2027 * 0.22x
Free-Float
93.93%
Yield 2026 *
-
Yield 2027 * -

Last Transcript: Precision Therapeutics Inc

Manager TitleAgeSince
Chief Executive Officer 57 09/02/2026
Director of Finance/CFO - 16/04/2026
President - 01/04/2026
Director TitleAgeSince
Director/Board Member 66 19/02/2020
Chairman 78 09/02/2026
Director/Board Member 60 09/07/2020
Change 5-day change 1-year change 3-year change Capi.($)
-7.56%-8.33% - - 96.21M
-0.21%-6.36%+49.00%+74.13% 66.34B
-0.22%+10.10%+12.77%+87.32% 52.92B
+0.82%+9.46%+7.75%+73.53% 54.82B
+3.28%+5.56%+26.48%+50.54% 44.09B
+0.51%+9.94%+22.39%+129.02% 43.72B
-1.15%+0.35%+263.06%+958.02% 42.13B
+0.10%+9.96%+17.15%+59.33% 33.96B
-1.30%-3.61%+37.37%+7.16% 26.17B
+0.69%+6.07%+31.89%+26.94% 23.37B
Average -0.40%+4.78%+51.99%+162.89% 43.06B
Weighted average by Cap. +0.42%+4.67%+51.32%+166.78%

Financials

2026 *2027 *
Net sales 60.4M 53.82M 49.83M 45.1M 84.96M 5.7B 85.97M 597M 234M 3B 227M 222M 9.55B 431M 384M 356M 322M 607M 40.7B 614M 4.27B 1.67B 21.39B 1.62B 1.58B 68.17B
Net income -41.4M -36.89M -34.16M -30.91M -58.23M -3.91B -58.92M -410M -161M -2.05B -155M -152M -6.54B -4.5M -4.01M -3.71M -3.36M -6.33M -425M -6.4M -44.51M -17.47M -223M -16.88M -16.53M -711M
Net Debt - -
Logo Precision Therapeutics Inc
Axe Compute Inc. is a virtual neocloud AI infrastructure platform. The Company provides customers with access to graphics processing unit (GPU) compute capacity for artificial intelligence (AI) and other high-performance computing workloads through a distributed network model, including infrastructure made available through the Aethir network. It also operates a digital asset treasury focused on the Aethir token (ATH), the native utility token of the Aethir network. Its segments include Compute Services and Treasury Management and Drug Discovery Services. Its Drug Discovery Services segment provides services that include the application of AI using its proprietary biobank of tumor samples, as well as creation of proprietary 3D culture models used in drug development. The Company provides enterprises and AI innovators with flexibility across hardware, geography, and deployment models through two offerings: Axe Compute Access and Axe Compute Build.
Employees
-